Company Reviews Significant Ophthalmology, Intellectual Property and Translational Development Milestones Achieved Over the Past Year

Palm Beach Gardens, FL, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company advancing topical metformin-based ophthalmic therapies for degenerative eye diseases, today issued the following letter to shareholders and interested investors reviewing the Company's progress over the past year and outlining its priorities as it advances its ophthalmology platform.